An Open Label Phase 2, Study to Evaluate the Safety and Efficacy of RGI-2001 for the Prevention of Acute Graft-vs-Host Disease Compared to Contemporary Controls in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 7
- 主要终点
- Grades II-IV aGVHD
研究概览
简要总结
This Phase II open label study will evaluate the safety and efficacy of repeat doses of RGI-2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT). These subjects will be compared to contemporary controls.
详细描述
This is an open-label, multi-center, single-arm study to evaluate six weekly doses of RGI-2001 in combination with standard of care treatment for the prevention of aGvHD in subjects following alloHSCT. The study will include a Safety Run-in Phase to assess the safety and tolerability of 6 weekly doses of RGI-2001 followed by an Expansion Phase in which the potential efficacy of 6 weekly doses of RGI-2001 in addition to standard of care for GvHD prophylaxis will be assessed. Comparison will be made to a contemporaneous control group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ages ≥ 18 and ≤ 65 years of age
- •Has a hematologic malignancy which includes Acute myelogenous leukemia (AML), T or B cell acute lymphoblastic leukemia (ALL) Myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), myeloproliferative disorder (MPD) including myeloid metaplasia and CML
- •Must have adequate organ function
- •Transplant Donor: Matched related donor or Unrelated donor
- •Is a candidate for anti-graft-vs-host-disease (GvHD) prophylaxis that includes a calcineurin inhibitor
- •Ability to understand and willingness to sign a written informed consent form
- •If female of childbearing potential, must have had a negative serum pregnancy test prior to enrollment and must have agreed to use a double barrier method of contraception for 30 days after RGI-2001 administration
- •If male, must be sterile or willing to use an approved method of contraception from the time of informed consent to 90 days after last dose of RGI-2001 administration
排除标准
- •Has had any other prior organ transplantation
- •Planned procedure to deplete regulatory T cells from donor transplant materials
- •Planned reduced intensity conditioning
- •Has had prior treatment with anti-CD3, other T cell depleting antibodies, or anti-thymocyte globulin within 12 months prior to alloHSCT procedure
- •Has progressive underlying malignant disease including post-transplant lymphoproliferative disease
- •Has evidence of active central nervous system (CNS) disease including known brain or leptomeningeal disease (CT or MRI scan of the brain required only in case of clinical suspicion of CNS involvement)
- •Is female and pregnant or lactating
- •Has a documented history of uncontrolled autoimmune disease or on active treatment
- •History of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to receiving study drug
研究组 & 干预措施
RGI-2001
Subjects will be administered RGI 2001 in combination with standard of care treatment
干预措施: RGI-2001 (Drug)
RGI-2001
Subjects will be administered RGI 2001 in combination with standard of care treatment
干预措施: Standard of Care (Drug)
结局指标
主要结局
Grades II-IV aGVHD
时间窗: Day 100 post-transplant
Acute GVHD will be graded and assessed according to modified KEYSTONE criteria and the severity grade (Grade II through IV) were captured up through the first 100 days post-transplant
次要结局
- Non-relapse Mortality (NRM) Rates(1 year post-transplant)
- Disease-free Survival (DFS)(1 year post-transplant)
- Overall Survival (OS)(1 year post-transplant)
- Grades II-IV aGVHD(Day 180 post-transplant)
- GvHD-free, Relapse Free Survival (GRFS)(1 year post-transplant)